Market Place
Sourcing Support
Eupraxia’s DiffuSphere™ Shows 6+ Months Targeted Drug Release
20 Nov 2024 //
#N/A
Eupraxia Pharmaceuticals to Present at ACR Convergence 2024
14 Nov 2024 //
PR NEWSWIRE
Eupraxia Pharma’s CEO to Join Webinar on Eosinophilic Esophagitis
13 Nov 2024 //
PR NEWSWIRE
Eupraxia Announce Positive Data from EP-104GI Trial for Esophagitis
12 Nov 2024 //
PR NEWSWIRE
Eupraxia Pharma Reports Q3 2024 Financial Results
07 Nov 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Closes C$44.5M Private Placement
31 Oct 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals to Present at Gastroenterology Meeting
28 Oct 2024 //
PR NEWSWIRE
Lancet Publishes Ph 2b Data On Eupraxia`s of Knee Osteoarthritis
15 Oct 2024 //
PR NEWSWIRE
Eupraxia To Present At United European Gastroenterology Week 2024
10 Oct 2024 //
PR NEWSWIRE
Renibus Shows RBT-1 Data At AMCP Nexus 2024 Meeting
03 Oct 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Strengthens Senior Management Team
02 Oct 2024 //
PR NEWSWIRE
Eupraxia Announces EP-104GI Phase 1b/2a Data For Eosinophilic Esophagitis
11 Sep 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals to Present at H.C. Wainwright Annual Conference
04 Sep 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
07 Aug 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
02 Aug 2024 //
PR NEWSWIRE
Eupraxia To Present At Controlled Release Society 2024 Annual Meeting
08 Jul 2024 //
PR NEWSWIRE
Eupraxia CEO To Join Webinar On Osteoarthritis Rise On July 9, 2024
03 Jul 2024 //
PR NEWSWIRE
Eupraxia Announces Voting Results From AGM And Special Meeting
06 Jun 2024 //
PR NEWSWIRE
Eupraxia Eoe Trial Expansion: Resolve Phase 1b/2a Ep-104gi Announced
23 May 2024 //
PR NEWSWIRE
Eupraxia Hosts KOL Event On EoE Program EP-104GI
22 May 2024 //
PR NEWSWIRE
Eupraxia Announces Positive RESOLVE EoE Phase 1b/2a EP-104GI Data
21 May 2024 //
PR NEWSWIRE
Eupraxia To Present EP-104GI Eosinophilic Esophagitis Data At DDW 2024
14 May 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals: Q1 2024 Financials, Corporate Update
08 May 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
02 May 2024 //
PR NEWSWIRE
Eupraxia Presenting At Osteoarthritis Congress 2024
11 Apr 2024 //
PR NEWSWIRE
Eupraxia To Present at Bloom Burton & Co. Healthcare Investor Conference
08 Apr 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
05 Apr 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
03 Apr 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
01 Apr 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering
15 Mar 2024 //
GLOBENEWSWIRE
Eupraxia Announces Pricing of Overnight Marketed Offering of $30 Million
12 Mar 2024 //
GLOBENEWSWIRE
Eupraxia Announces Overnight Marketed Offering of Approximately $30 Million
11 Mar 2024 //
GLOBENEWSWIRE
Eupraxia Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial
26 Jun 2023 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Appoints CBO
01 Nov 2022 //
NEWSWIRE
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering
12 Apr 2022 //
GLOBENEWSWIRE
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering
11 Apr 2022 //
GLOBENEWSWIRE
